Quest Diagnostics (DGX) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Recent performance and guidance

• Raised 2024 EPS guidance by $0.05 to $8.90 and revenue by $100 million to about $9.54 billion, reflecting strong organic growth and recent acquisitions.

• Organic revenue growth in the back half of 2024 is projected at 3.5%-4%, with total base revenue growth around 5% including acquisitions.

• LifeLabs acquisition in Canada closed earlier than expected, contributing $710 million in revenue and $0.10-$0.15 EPS accretion in the first 12 months.

• Advanced diagnostics and test mix improvements are driving higher revenue per requisition, supported by investments in brain health, cardiovascular, and autoimmune testing.

• Haystack early experience program launched, with national rollout planned for Q4 2024 and reduced dilution expected in 2025.

Market trends and growth drivers

• Canadian lab market expected to grow 3-4% annually, with opportunities for advanced and consumer testing due to favorable demographics and established pricing.

• U.S. organic growth driven by increased test density, favorable payer mix, and a shift of volume from hospital to independent labs.

• Payers are actively steering patients to independent labs for cost savings, contributing to industry volume growth.

• Hospital outreach deals in Minneapolis, Columbus, and Cleveland provide new market footholds and growth potential.

Payer relationships and contract dynamics

• Over 50% of contracts now include value-based arrangements, with incentives tied to volume shifts and patient satisfaction.

• Pricing with health plans is slightly up post-COVID, while health system pricing remains challenged.

• About 25% of contracts are renewed annually, with most 2024 negotiations completed and outlook stable for 2025.